This website is intended for healthcare professionals only.
WHERE DO WE STAND IN MPaCa?
Prof. Thomas Seufferlein Medical Director Department of Internal Medicine I University Hospital Ulm, Germany
This webinar highlights the current treatment landscape as well as treatment goals in mPaCa, with a presentation of the different clinical trials and real-world studies of 1L and 2L treatment options. It also introduces tailored treatment for specific patients, based on genomics and phenomics.
Key points covered
This webinar discusses the current treatment options and strategies in mPaCa.
There is now the option for sequential treatment in mPaCa; 1L and 2L choices should be based on the patient's needs and treatment history.
mPaCa has high genomic heterogeneity; targeted treatment could benefit certain specific patient subgroups (MSI-H, gBTAC1/2, KRAS WT)
Phenomics (organoid-based approaches) may also support choosing the right treatment
Webinar Replay
Featured Speakers
Prof. Thomas Seufferlein
Prof Dr Thomas Seufferlein is a MD, PhD who obtained his doctorate at the II. medical clinic of the Klinikum Rechts der Isar of the Technical University of Munich. From Berlin he moved to London, where he worked at the Imperial Cancer Research Fund (now: Cancer Research UK) as a postdoc in the laboratory of Dr E. Rozengurt for several years. After his postdoctoral period, he continued his clinical activities in Ulm at the Department of Internal Medicine I and obtained a specialist degree in Internal Medicine and a specialization in Gastroenterology and is now the director of this department.
He is the chairman of the Committee for Cancer Prevention of the German Cancer Aid and spokesman of the Oncological Guidelines Program of the DKG, German Cancer Aid and the AWMF. The main focus of Thomas Seufferlein’s scientific work in the clinical and basic scientific fields is gastrointestinal tumors, in particular pancreatic cancer.
